Form 4: Exact Sciences CEO Kevin Conroy Acquires $1 Million in Company Stock

Exact Sciences CEO Kevin Conroy purchased 19,500 shares of company stock for approximately $1 million, increasing his total holdings.

Summary

• Kevin Conroy, the President and CEO of Exact Sciences Corp, purchased 19,500 shares of the company's common stock on November 13, 2024.
• The purchase was made on the open market at a price of $51.35 per share, totaling $1,001,325.
• Following this transaction, Mr. Conroy directly owns 1,074,191 shares of common stock.
• He also indirectly owns 28,084 shares through a 401(k) plan and 310,306 shares through various Grantor Retained Annuity Trusts.
• In addition to the common stock, Mr. Conroy holds 683,018 vested and unvested options and restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is positive as the CEO is investing a significant amount of his own money in the company, which is generally seen as a good sign. However, it is a routine filing and not a major event.

Positives

• The CEO's purchase of shares demonstrates confidence in the company's future.
• The purchase was a significant investment of over $1 million.

Industry Context

This is a routine SEC Form 4 filing, which is common when company insiders make transactions in their company's stock. It is a standard practice for executives to hold and trade shares in their own companies.

Comparison to Industry Standards

• Executive stock purchases are common across publicly traded companies, and this transaction is within the normal range for a CEO of a company of Exact Sciences' size.
• Similar filings are made by executives at companies like Guardant Health, Illumina, and Myriad Genetics when they buy or sell shares.

Stakeholder Impact

• The CEO's stock purchase may positively influence investor confidence.
• The purchase does not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Exact Sciences, Kevin Conroy, stock purchase, insider trading, SEC Form 4, executive holdings, EXAS